Please login first

The 1st International Electronic Conference on Vaccines

RNA Vaccines, Current Challenges and Future Developments

1–15 Dec 2023

Immunological Mechanisms, Viral Immunology, Immunopathogenesis, Vaccine Development and Efficacy Evaluation, Immune Responses to Vaccines, Vaccine Technology, Vaccine Vectors Adjuvants and Immunomodulators, Immunomodulation, Prophylactic Vaccines
Bookmark
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Contact Us

Live Sessions Information


During the duration of the conference, TWO live online sessions will be programmed. The live streaming platform we are using is Zoom. During each session, the participants will have the possibility to ask questions during a Q&A session. Detailed information about the topics and dates will be shared soon.

The live sessions are free of charge. The authors who submit submissions to IECV 2023 will have priority for the registration (with no extra cost) to the live online sessions with our keynote speakers. If it is not completely full, registration will be open for unregistered participants. Registrations with academic institutional email addresses will be prioritized. The number of participants in the live session is limited but the recording will be made available on Sciforum shortly afterward.

We are pleased to invite you to subscribe to our conference so that you can receive email notifications when the live session program is online and open online discussions.

Live sessions

1 December 2023 (Friday)
(Closed)

CET

EST

CST Asia

Speaker

09:00 - 09:10

3:00-3:10 16:00-16:10 Prof. Dr. Silvio Tafuri
Welcome message

09:10 - 09:40

3:10-3:40 16:10-16:40

Prof. Dr. Silvio Tafuri and Dr. Antonio Di Lorenzo
The progress of Polio eradication

09:40 - 10:10

3:40-4:10 16:40-17:10 Prof. Dr. Hidehiro Fukuyama
Transdermal adjuvant for next-generation vaccines

10:10 - 10:40

4:10-4:40 17:10-17:40

Prof. Dr. S. Louise Cosby
Large animal challenge models for assessment of veterinary and human vaccines

4 December 2023 (Monday)

CET

EST

CST Asia

Speaker

14:00-14:10

8:00-8:10 21:00-21:10 Prof. Dr. François Meurens
Welcome message

14:10-14:40

8:10-8:40 21:10-21:40

Prof. Dr. Ger Rijkers
The Impact of SARS-CoV-2 Immune Status and Societal Restrictions in Controlling COVID-19 across the World.

14:40-15:10

8:40-9:10 21:40-22:10 Prof. Dr. Ranjit Ray
Modified envelope glycoproteins and the use of mRNA-LNP platform as hepatitis C virus candidate vaccine

15:10-15:40

9:10-9:40 22:10-22:40 Prof. Dr. Vishwanath Venketaraman
g\Glutathione improves host immune responses against Mycobacterium tuberculosis infection

Live Session Recordings

To view this content, you need to be registered and logged in to Sciforum platform.

Keynote Speakers

Science Department, University College Roosevelt, Middelburg, The Netherlands; St. Elisabeth Hospital, Tilburg, The Netherlands

DETAILS
Research Keywords
mucosal immunology; immunoregulation (in autoimmune diseases, allergic diseases and infections); interaction between gut microbiota and the immune system; vaccination

Invited Speakers

Division of Immunology, Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical School, Japan

School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK

Division of Infectious Diseases, Allergy & Immunology, Saint Louis University, USA

Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Italy

Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, USA

Welcome from the Chairs

Dear colleagues,

We are pleased to announce the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV 2023), which will be held on 1–15 December 2023.

mRNA vaccines have been developed and trialled for cancers and infectious diseases. Although the success of mRNA vaccines has been achieved in the control of COVID-19, there are challenges for future development. The production of mRNA vaccines requires multiple steps including mRNA synthesis, purification, and formulation with, e.g., lipid nanoparticles. Therefore, the stability of intermediate and final products during storage and transportation is a real problem. Breakthrough infections of SARS-CoV-2 variants and the immune evasion of cancers driven by the mutation of antigens expressed from mRNA are the major challenges in development. Since mRNA vaccines have shown advantages compared to others due to the induction of humoral and cellular immune responses and adaptability in viral and tumour antigens, future vaccines should be stabler, safer, and more compatible with other regimens in combination with other options.

All vaccine-related scientists or researchers are welcome to join this event and share their findings around the following general and related themes including but not limited to:
  • Vaccines to counter anti-microbial resistance;
  • Vaccines to eradicate endemic disease-opportunities and challenges;
  • Vaccines to prevent zoonotic transmission-targeting the animal reservoir;
  • Vaccine platforms—advantages and disadvantages;
  • Clinical trial design for reactive and preventive vaccination;
  • Vaccine deployment in outbreak settings—lessons learned;
  • Advances in vaccine formulation and adjuvantisation;
  • Clinical view on routinisation of RNA vaccines;
  • How do we prepare for vaccines against the as yet unknown?;
  • COVID-19 Vaccine Hesitancy;
  • Immune Response after Vaccination against SARS-CoV-2 in Patients with Chronic Diseases;
  • T Cell Responses in SARS-CoV-2;
  • SARS-CoV-2 Variant and Vaccines Development;
  • Novel Technology and Vaccines Development for COVID-19;
  • T Cell Immunity and HIV-1 Pathogenicity;
  • Neurological Complications Following COVID-19 Infection and COVID-19 Vaccination;
  • Vaccine hesitancy;
  • Vaccine safety;
  • Vaccine ingredients;
  • Vaccine schedule;
  • Vaccine objections;
  • Vaccines influence on education;
  • Cost-Effectiveness of vaccines;
  • Vaccine transportation;
  • Methods of Vaccination;
  • Vaccine-related policy.
The participants will have the opportunity to examine, explore, and critically engage with issues and advances in these areas. We hope to facilitate discussions and exchanges within the community. This event will solely be an online proceeding, which allows for participation from all over the world with no concerns about travel and related expenditures. This type of conference is particularly appropriate and useful because research concerned with vaccines is progressing rapidly and globally. An electronic conference provides a platform for rapid and direct exchanges about the latest research findings and novel ideas. Participation in as well as the “attendance” of this online conference is free of charge.

We hope that the community will share this enthusiasm and help ensure this conference a success.


The Chair of the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments

Follow the conference organizer on Social Media

Event Chairs

Swine and Poultry Infectious Diseases Research Center (CRIPA), Faculty of Veterinary Medicine, University of Montreal, Canada

DETAILS
Bio
François Meurens a réalisé ses études de médecine vétérinaire en Belgique (Université Catholique de Louvain et Université de Liège) où il a obtenu son diplôme en 2000. En 2001, il a obtenu sa maîtrise en Sciences Vétérinaires (orientation virologie) et en 2004 il a terminé sa thèse de doctorat en Sciences Vétérinaires après avoir étudié la recombinaison génétique chez les alphaherpèsvirus de ruminants (Laboratoire du Professeur Etienne Thiry). Ensuite il a effectué un post-doctorat à VIDO-InterVac à l’Université de la Saskatchewan (Canada) pendant deux ans. Là-bas il s’est intéressé à l’immunologie des muqueuses dans les espèces porcine et ovine (laboratoire du Pr Volker Gerdts). Fin 2006 il a intégré l’INRA de Tours (unité ISP) en qualité de chargé de recherche. Sur place il a animé une équipe spécialisée dans l’étude des relations hôte/pathogène dans le modèle porcin. En 2012 il a ensuite accepté un poste de Scientique/Professeur adjoint à VIDO-InterVac (Canada) où il a animé une équipe sur des thématiques très similaires à celles développées en France. Une attention particulière a été portée à l’intérêt du porc en tant qu’espèce modèle pour la recherche biomédicale humaine. Auteurs de nombreuses publications dans des journaux internationaux à comité de lecture et exerçant des activités d’experts pour le secteur privé et dans les comités éditoriaux des revues Veterinary Immunology and Immunopathology et Frontiers in Veterinary Medicine, le Dr Meurens s’est orienté en 2015 vers une carrière plus académique alliant l’enseignement à la recherche scientifique à Oniris. Depuis lors il exerce son activité d’enseignement en microbiologie/immunologie et son activité de recherche au sein de l’UMR BioEpAR.
Email
francois.meurens@umontreal.ca

INRAE, Oniris, BIOEPAR, France

DETAILS
Bio
Short biography Fanny Renois (PhD, HDR) began her career as an immuno-virologist at the Faculty of Medicine and the University Hospital of Reims (France). Her first project focused on Picornaviridae with respiratory tropism in humans, which were awarded the RICAI Prize in 2012. Then, Fanny Renois developed her research on the elucidation of the role of Coxsackieviruses and their mechanism of action in the development of dilated cardiomyopathies and sudden death in young adults. Since 2016, Fanny Renois has been an associate professor of public health at the National Veterinary School of Nantes (France). Currently, she is developing research to understand the molecular aspects of the innate immune response developed against multiple respiratory viruses in the porcine species.
Email
fanny.renois@umontreal.ca

Session Chairs

Dr. Silvio Tafuri

Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Italy

DETAILS
Short Bio
Silvio Tafuri was born in Brindisi (Italy) on 1980, 17 August. He graduated in Medicine and Surgery at Bari School of Medicine in 2005; In 2008, he achieved post-degree in Public Health and since 2013 he is Ph.D. in Hygiene, Public Health and Food Safety. He is a consultant of the Apulian Observatory for Epidemiology in the field of vaccination strategies, surveillance of infectious diseases and of adverse events following immunization. From 2014 to March 2020, he has been Assistant Professor of Public Health at the Bari School of Medicine; since March 2020 to April 2021, he was Associate Professor of Public Health. From April 2021, he is Full Professor at the University of Bari. He works as consultant in the Public Health Unit of the Policlinico Bari General Hospital, in which he is charged of the management of vaccination activities; since March 2020, he is Chief of the Control Room Unit and of the Infection Control Program Team. He is author of 280 articles published in international scientific journals (IF >700, h-index 27); the major part of scientific paper is in the field of vaccinology and of the prevention of infectious diseases.

Prof. Dr. Martin J. D'Souza

Department of Pharmaceutical Sciences, Mercer University, USA

DETAILS
Short Bio
Dr. D’Souza’s Nanotechnology laboratory mainly focuses on the design and delivery of both Buccal vaccines using oral dissolving film (ODF) and Transdermal vaccines using microneedles for infectious diseases and cancer. Currently Dr. D’Souza’s lab is focusing vaccines for Infectious diseases such as SARS CoV-2, Universal Influenza, RSV, Zika, and Gonorrhea – to name a few. Additionally, work is underway on therapeutic vaccines for cancers such as Melanoma, Ovarian, Prostate ad Breast. Dr. D’Souza has graduated over 60 Ph.D. students and has published over 150 manuscripts. He has been the recipient of several research grants from the National Institutes of Health (NIH), the American Diabetes Association, the Georgia Cancer Coalition, the Georgia Research, Alliance. He serves as an Executive Editor, and is on the Editorial Boards of over 10 Scientific Journals. He has several patents issued in the area of Nanotechnology. Currently, he has several active NIH funded research grants

Dr. Siddappa N. Byrareddy

1. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, USA 2. Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, USA 3. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, USA

DETAILS
Short Bio
Dr. Siddappa Byrareddy, Ph.D., is currently a Professor & Vice Chair of Research in the department of Pharmacology & Experimental Neuroscience at the University of Nebraska Medical Center, Omaha, NE, USA. Dr. Byrareddy's current research interests include understanding and developing therapeutics for emerging and reemerging infectious diseases focusing on HIV, Zika, and SARS-CoV-2. His lab emphasizes understanding viral reservoirs (including T cells and myeloid cells), inflammation, and developing antivirals, vaccines and animal models for infectious diseases. Dr. Byrareddy's research is supported by multiple NIH awards (R01s, U01, R21), he serves on numerous review panels and has published more than 170 refereed journal articles

Dr. Daniel Dory

ANSES - FRENCH AGENCY FOR FOOD, ENVIRONMENTAL AND OCCUPATIONAL HEALTH & SAFETY Laboratory of Ploufragan/Plouzane/Niort Viral Genetics and Biosafety, France

DETAILS
Short Bio
Daniel DORY performed a first post-doc at the University Hospital of Basel (Switzerland) where he studied cellular receptors involved in the innate immune responses against bacteria. Thereafter he moved to ANSES (France) where he invistigated different strategies to improve DNA vaccination efficacy in pigs against infectious diseases (adjuvants, plasmid backbones, electroporation, heterologous prime-boost regimen …). He studied also the biodistribution of plasmid DNA upon intramuscular injection in pigs. DNA vaccination was also applied in chickens and in fish.

Dr. Angelos Hatzakis

Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens Medical School, Greece; Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases, Greece; Hepatitis B and C Public Policy Association, Luxembourg

DETAILS
Short Bio
Short biography Angelos Hatzakis MD, PhD Professor of Epidemiology and Preventive Medicine Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, Medical School Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases Former President of the Hellenic Center for Disease Control & Prevention. Founder of the National Retrovirus Reference Center, Athens, Greece. Founder and Co-Chair of “Hepatitis B & C Public Policy Association”, Luxembourg. Participation in many Executive Committees of public and private sector. His research interests cover epidemiology, virology, preventive medicine, Public Health and infectious diseases, especially HIV/AIDS, hepatitis, COVID-19, and pandemic viruses, harm reduction and mortality patterns of PWID’S. Author or co-author of more than 350 scientific papers published in Journals like Lancet, Lancet HIV, Lancet Gastroenterology and Hepatology, JAMA, British Medical Journal, Annals of Internal Medicine, PNAS, Hepatology, Gastroenterology, AIDS, Journal of AIDS, Journal of Infectious Diseases, Clinical Infectious Diseases, Blood, Cancer Research, Pediatrics etc. with more than 21.000 citations.

Event Committees

Department of Public Health Policy, School of Public Health, University of West Attica, Greece

DETAILS
Bio
Dimitris Zavras is Assistant Professor of Health Services Research and Health Economics at the Department of Public Health Policy at the University of West Attica. Along his academic, educational and research responsibilities he serves as Director of the Division of Health Systems and Policy. He is also Faculty Member of the Hellenic Open University. Dimitris was born in Athens in 1968 and studied Physics at the National & Kapodistrian University of Athens. His postgraduate studies include an M.Sc. in Applied Physics from the University of Massachusetts; M.Sc. in Statistics from Athens University of Economics and Business; M.Sc. in Healthcare Management from the National School of Public Health; and a Doctorate (Ph.D.) in Health Services Research and Health Economics from the University of Thessaly (Department of Economics). Dimitris has taught in postgraduate programs of the University of West Attica, the University of Peloponnese, the Neapolis University Pafos (Cyprus), and the National School of Public Health and in undergraduate programs of the University of West Attica, the University of Peloponnese and the Athens University of Applied Sciences. Dimitris Zavras’ research interests focus on healthcare access and economics, the utilization of healthcare services, healthcare provider choice, and unmet healthcare needs. His most recent research work and published articles deal with economic issues surrounding the COVID-19 pandemic. He is a member of the International Health Economics Association, the Hellenic Scientific Society of Health Economics and Health Policy and the Hellenic Society of Public Health. He is also a member of the Hellenic Society for Healthcare Services Management.
Research Keywords
Healthcare access; utilization of healthcare services; healthcare provider choice; unmet healthcare needs; access to the COVID-19 vaccine; economic impact of the COVID-19 pandemic; vaccination

University of Chicago, Argonne National Laboratory, USA

DETAILS
Bio
I received a Ph.D. in microbiology from Zhejiang University, China in 2015, where I studied oxidative stress adaption and flagellar regulation of Shewanella oneidensis. I then continued my training as a postdoctoral scholar at the University of Chicago’s Department of Microbiology since 2015 with focusing on pathogenesis of Staphylococcus aureus and vaccine development. until 2019, and currently is a research professional at the University of Chicago’s Howard Taylor Ricketts Laboratory.
Research Keywords
Staphylococcus aurues, phathogenesis, vaccine, antibody engineering

12735 Twinbrook pkwy 3W05 Laboratory of Malaria and Vector Research National Institute of Allergy and Infectious Disease National Institutes of Health Rockville, USA

DETAILS
Bio
Gagandeep Singh Saggu completed his Ph.D. in Molecular parasitology from the Department of Biological Sciences, BITS, Pilani, Pilani Campus. He was awarded a Junior and Senior Research Fellowship (Dec 2010) from the Council of Scientific and Industrial Research and University Grant Commission, Govt. of India to pursue Ph.D. During his Ph.D. He has published research articles in journals of international repute and has presented his research work at national and international conferences and workshops. He joined the National Institute of Allergy and Infectious Diseases, NIH as a Postdoctoral Research Fellow. In NIAID he continued his research work in the field of parasitology and with the help of Patch-clamp identified a novel ion channel/transporter on the digestive vacuole membrane of the malaria parasite. He was successful to study the various properties and selectivity of these channels. He is in the process of molecular characterization of these channels which will provide foundational insights into vacuolar biology, clarify the resistance mechanisms for several antimalarial drugs, and guide the development of new therapies for malaria. For his current research, he received the ASTMH research excellence award in the field of molecular biology and the Fellowship Award for Research Excellence (FARE 2019) from NIH.
Research Keywords
Malaria, Plasmodium, Electrophysiology, CRISPR, Parasite transfection, Advance microscopy

Turiba University, Latvia

DETAILS
Bio
Greg Simons was born in New Zealand in 1969 and graduating with a PhD from the University of Canterbury in 2004, and promoted to Associate Professor by the Department of Government at Uppsala University in 2015. Greg Simons is currently a researcher at the Institute for Russian and Eurasian Studies (IRES) at Uppsala University, and a lecturer at the Department of Communication Science at Turiba University in Riga, Latvia.
Research Keywords
crisis management and crisis communications (including public health issues), changing political dynamics and relationships, mass media, public diplomacy, political marketing, media and armed conflict, and the Russian Orthodox Church

1. Laboratory of Computing, Medical Informatics and Biomedical - Imaging Technologies, School of Medicine. Aristotle University of Thessaloniki   2. International Hellenic University

DETAILS
Bio
34 publications in international scientific journals, more than 55 announcements to international scientific conferences; 2011 School of Biology, AUTH 2013 MSc in Applied Genetics and Biotechnology, School of Biology, AUTH 2018 PhD in Human Genetics-Immunogenetics , School of Medicine, AUTH 2019 Post-doc researcher in School of Medicine, AUTH 2020 MSc in Medical Informatics, School of Medicine, AUTH
Research Keywords
Genetics/Immunogenetics, Next Generation Sequencing, Flow cytometry

School of Public Health, The University of Hong Kong

DETAILS
Bio
Dr. Zanin received his PhD in Microbiology from Monash University in Melbourne, Australia and underwent postdoctoral training in influenza virology at St. Jude Children’s Research Hospital in Memphis, TN, USA with Dr. Robert Webster and Dr. Richard Webby. He subsequently established a research group at the State Key Laboratory of Respiratory Diseases in Guangzhou, China to study the emergence and transmission of zoonotic respiratory viruses.
Research Keywords
Dr. Zanin’s research interests are the host and viral factors underlying transmission of respiratory viruses and interventions against viral respiratory diseases.

University of Cologne, Faculty of Medicine, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM) and Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Germany

DETAILS
Bio
Dr. Jon Salmanton-García, PhD in Health Sciences by the University of Cologne (Cologne, Germany) is a postdoctoral researcher and project manager in the group of Prof. Dr. Oliver A. Cornely, Department I of Internal Medicine, University Hospital Cologne (Cologne, Germany). He did his PhD thesis on emerging invasive fungal infections, namely mucormycosis, and extremely rare invasive fungal infections within the FungiScope – Global Registry of Emerging Fungal Infections team (www.fungiscope.net). Currently, he is a member of the Coordination Office of the VACCELERATE Consortium, a pan European clinical research network for the coordination and conduction of COVID-19 vaccine trials (www.vaccelerate.eu), managing the EUVAP – European Vaccine Trial Accelerator Platform (www.euvap.eu), so as the VACCELERATE Volunteer Registry (www.vaccelerate.eu/volunteer-registry). In parallel, he also coordinates the EPICOVIDEHA survey – Epidemiology of COVID-19 infection in patients with haematological malignancies: A European Haematology Association Survey (www.ehaweb.org/covid-19/epicovideha-survey/). Additionally, he is in charge of the research series “The current state of laboratory mycology in…”, an online survey where institutions from different geographical regions are being asked about their diagnostic and treatment capacities for invasive fungal infections.
Research Keywords
He has a special interest in registries and questionnaires, database management, invasive fungal infections and infectious diseases in general.

Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, China

DETAILS
Bio
Li Yin: Doctor of Preventive Veterinary Medicine, Researcher. He is a master’s degree supervisor at Nanjing Agricultural University and Jiangsu University, and a postdoctoral supervisor at the postdoctoral station of Jiangsu Academy of Agricultural Sciences. Main research content and direction: The mutation, cross-host transmission mechanism, and prevention and control of avian influenza virus subtype H9; the influence mechanism of structural and non-structural proteins of waterfowl tembusu virus on virulence, pathogenicity and immunogenicity of the virus and its prevention and control; the epidemiological investigation, pathogenic mechanisms, and prevention and control of the goose astrovirus. Waterfowl Disease Prevention and Control Innovation Team, Institute of Veterinary Research, Jiangsu Academy of Agricultural Science.

Coxiella Pathogenesis Section, Laboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA

DETAILS
Bio
Dr. Long graduated summa cum laude from Gardner-Webb University with a B.S. in 2011. She received her Ph.D. in immunology and microbial pathogenesis from West Virginia University in 2016. Here, she studied the role of regulatory T cells and microRNAs in chemical allergy at the National Institute for Occupational Safety and Health (CDC). After earning her doctorate, Dr. Long moved to Hamilton, Montana, to join Dr. Robert Heinzen's group at the National Institutes of Health to work as an Intramural Research Training Award postdoctoral fellow. During this time, Dr. Long worked in the biosafety level 3 laboratory researching the causative agent of Q fever, Coxiella burnetii. She investigated both bacterial and host factors required for virulence and refined guinea pig models for infection, vaccination, and post-vaccination hypersensitivity. In 2019, Dr. Long received an Independent Research Scholar Award from NIH, allowing her to form an autonomous research group to continue her work on Coxiella burnetii.
Research Keywords
Coxiella burnetii, bacterial vaccines, bacterial genetics, adaptive immune responses, host-pathogen interactions, dermal allergy, post-vaccination hypersensitivity, Q fever, lipopolysaccharide

Instructions for Authors

Procedure for Submission
Submissions should be made online by authors by registering with and using the “New Submission” function once logged into the system.

Note:
Institutional email address is requested especially for the corresponding author. Please submit the abstract along with an institutional email address.

1. Scholars interested in participating in the conference can submit their abstract (about 200–300 words) online on this website until

11th July 2023 15th September 2023 . The Conference Committee will notify regarding acceptance of the abstract by 25th July 2023 27th September 2023.
2. In case of acceptance, authors will be asked to submit their manuscript (short proceedings paper, 3–6 pages), a poster, a slide presentation (in PDF), or a short video presentation (max. 3–5minutes) before 13th September 2023 20th October 2023. Authors will receive notification about the acceptance of their paper by 30th September 2023 20th November 2023.
3. The manuscripts and presentations will be available on Sciforum.net for discussion and rating during the time of the conference, 1–15 December 2023.

Note: All submissions will be reviewed using the powerful text comparison tool iThenticate. This procedure aims to prevent scholarly and professional plagiarism. Submissions will then be peer-reviewed by conference committees based on originality/novelty, quality of presentation, scientific soundness, interest to the readers, overall merit, and English level. After the conference, all submissions will be published on sciforum.net, and only the proceeding paper (3-6 pages) will be published in the MDPI Medical Sciences Forum journal (ISSN 2673-9992).
Note: Publication of proceedings paper is free of charge. Before publication, Medical Sciences Forum journal will check the plagiarism issue again. Submissions with a lack of novelty will not be published in the journal.

The submission to the Special Issue is independent of the conference proceedings and will follow the usual process of the journal, including peer review, APC, etc. All participants of IECV 2023 are welcome to submit an extended full paper to the conference Special Issue "Selected Papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023)" of the journal Vaccines, with a 20% discount on the article processing charge.

Proceedings Papers
Proceedings papers must be prepared in MS Word using the template (See below) and should be converted to PDF format before submission. The manuscript should be at least 3 pages (incl. figures, tables, and references) and should not exceed 6 pages. Please carefully read the rules outlined in the Instructions for Authors on the journal website and ensure that your manuscript submission adheres to these guidelines.

Manuscripts for the proceedings issue must be structured as follows:
  • Title
  • Full author names
  • Affiliations (including full postal address) and authors’ e-mail addresses
  • Abstract
  • Keywords
  • Introduction
  • Methods
  • Results and Discussion
  • Conclusions
  • (Acknowledgments)
  • References
Slide Presentations
Authors are encouraged to prepare a presentation in PowerPoint (or similar) software, to be displayed online. Slides can be prepared in the same way as for any traditional conference. They should be converted to PDF format before submission.

Video Presentations
Videos should be no longer than 3–5 minutes and prepared in one of the following formats: .mp4/.webm/.ogg (max size: 250 Mb). These should be submitted before 13th September 2023 (full submission deadline).

Posters
Posters will be available on the conference website during and after the event. Similarly to papers presented at the conference, participants will be able to ask questions and make comments about the posters.
1)The poster should be in PDF format
2)The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
3)The content of the poster should be a comprehensive presentation of your accepted submission.
4) No copyright issues with any elements in the poster.

Potential Conflicts of Interest
All authors must disclose all relationships or interests that could inappropriately influence or bias their work. This should be conveyed in a separate “Conflict of Interest” statement preceding the “Acknowledgments” and “References” sections at the end of the manuscript. If there is no conflict, please state “The authors declare no conflicts of interest”. Financial support for the study must be fully disclosed under the “Acknowledgments” section.

Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).

List of accepted submissions (6)

Id Title Authors Presentation Video Poster PDF
sciforum-080812 Perception, attitude and intention towards COVID-19 vaccination

, , ,

Submitted: 26 Oct 2023

Abstract: Show Abstract
, , , N/A Poster PDF Show Abstract
sciforum-080541 Impact of COVID-19 on Influenza Virus Vaccination Coverage

, , ,

Submitted: 07 Sep 2023

Abstract: Show Abstract
, , , N/A N/A Show Abstract
sciforum-074340 Challenges faced by states and the WHO in regulating efficiently the use of mRNA vaccines



Submitted: 23 May 2023

Abstract: Show Abstract
N/A N/A Show Abstract
sciforum-072818 Factors driving the attitudes and hesitancy of Albanian parents toward Covid-19 vaccination of children.

,

Submitted: 13 Apr 2023

Abstract: Show Abstract
, N/A N/A Show Abstract
sciforum-080932 Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis

, , , , ,

Submitted: 14 Oct 2023

Abstract: Show Abstract
, , , , , N/A Poster PDF Show Abstract

Event Awards



To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide one Best Paper Award and one Best Presentation Award.

The Awards
Best Paper Award - 500 CHF

Number of Awards Available: 1

Vaccines would like to grant an award for the best paper as elected by the conference committee.

Terms and Conditions:

  • Proceedings paper (3–6 pages) must be submitted to IECV 2023;
  • Originality/Novelty of the paper;
  • Significance of Content;
  • Scientific Soundness;
  • Interest to the readers;
  • English language and style.
Best Presentation Award - 500 CHF

Number of Awards Available: 1

Vaccines would like to grant an award for the best presentation at the conference as determined by a jury. Poster/Slides/Video Presentations will be considered for this award.

Presentations should have the following information:

  • Title (with authors and affiliations)
  • Introduction/Objectives/Aims
  • Methods
  • Results
  • Conclusion
  • Acknowledgments
  • Contact information

Conference Secretariat

Ms. Cynthia Wang
Ms. Alethea Liu

For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
E-Mail: iecv@mdpi.com

Sponsors and Partners

Organizers


Media Partners

Top